{
    "clinical_study": {
        "@rank": "158345", 
        "arm_group": [
            {
                "arm_group_label": "Cohort 1", 
                "arm_group_type": "Experimental", 
                "description": "0.04 mg/kg CpG 7909"
            }, 
            {
                "arm_group_label": "Cohort 2", 
                "arm_group_type": "Experimental", 
                "description": "0.08 mg/kg CpG 7909"
            }, 
            {
                "arm_group_label": "Cohort 3", 
                "arm_group_type": "Experimental", 
                "description": "0.12 mg/kg CpG 7909 Injection once weekly"
            }, 
            {
                "arm_group_label": "Cohort 4", 
                "arm_group_type": "Experimental", 
                "description": "0.16 mg/kg CpG 7909"
            }
        ], 
        "brief_summary": {
            "textblock": "To determine the safety and efficacy of CPG 7909 Injection given with Herceptin to patients\n      with metastatic breast cancer."
        }, 
        "brief_title": "CPG 7909 Plus Herceptin\u00ae In Patients With Metastatic Breast Cancer", 
        "completion_date": {
            "#text": "October 2003", 
            "@type": "Actual"
        }, 
        "condition": "Carcinoma, Breast", 
        "condition_browse": {
            "mesh_term": [
                "Breast Neoplasms", 
                "Carcinoma"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Histologically confirmed breast cancer with metastases\n\n          -  Tumor that has overexpression of HER2 as documented by being either FISH-positive or\n             HER2/neu 3+ confirmed by immunohistochemistry\n\n          -  Patients may have had up to three prior chemotherapy regimens for metastatic disease,\n             which may have been given in combination with Herceptin\u00ae and which may have been\n             discontinued due to toxicities.  In addition, patients may have had adjuvant\n             chemotherapy.\n\n          -  Phase II only: Must have measurable disease by RECIST criteria (defined in section 8)\n             with at least one lesion that can be accurately measured in at least one dimension\n             (longest diameter to be recorded) as > 20 mm with conventional techniques, or as > 10\n             mm with spiral CT scan\n\n        Exclusion Criteria:\n\n          -  Any prior therapy with anthracycline + Herceptin\u00ae  concurrently\n\n          -  Significant cardiovascular disease (e.g., NYHA class 3 congestive heart failure,\n             myocardial infarction within the past 6 months, unstable angina; coronary angioplasty\n             within the past 6 months, uncontrolled atrial or ventricular cardiac arrhythmias) or\n             left ventricular ejection fraction < 50%\n\n          -  Pre-existing autoimmune or antibody-mediated diseases including but not limited to:\n             systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, Sjogren's\n             syndrome, autoimmune thrombocytopenia"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "16", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "August 8, 2002", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00043394", 
            "org_study_id": "C015", 
            "secondary_id": "A8501021, CO15"
        }, 
        "intervention": [
            {
                "arm_group_label": "Cohort 1", 
                "description": "0.04 mg/kg CpG 7909 by subcutaneous Injection once weekly until progression or 24 weeks", 
                "intervention_name": "0.04 mg/kg CpG 7909", 
                "intervention_type": "Drug", 
                "other_name": "PF-03512676, ProMune"
            }, 
            {
                "arm_group_label": "Cohort 1", 
                "description": "Herceptin\u00ae (maintenance dose per the manufacturer's directions) followed by a subcutaneous injection of CpG 7909.", 
                "intervention_name": "Herceptin\u00ae", 
                "intervention_type": "Drug", 
                "other_name": "Trastuzumab"
            }, 
            {
                "arm_group_label": "Cohort 2", 
                "description": "0.08 mg/kg CpG 7909 by subcutaneous Injection once weekly until progression or 24 weeks", 
                "intervention_name": "0.08 mg/kg CpG 7909", 
                "intervention_type": "Drug", 
                "other_name": "PF-03512676, ProMune"
            }, 
            {
                "arm_group_label": "Cohort 2", 
                "description": "Herceptin\u00ae (maintenance dose per the manufacturer's directions) followed by a subcutaneous injection of CpG 7909.", 
                "intervention_name": "Herceptin\u00ae", 
                "intervention_type": "Drug", 
                "other_name": "Trastuzumab"
            }, 
            {
                "arm_group_label": "Cohort 3", 
                "description": "0.12 mg/kg CpG 7909 by subcutaneous Injection once weekly until progression or 24 weeks", 
                "intervention_name": "0.12 mg/kg CpG 7909", 
                "intervention_type": "Drug", 
                "other_name": "PF-03512676, ProMune"
            }, 
            {
                "arm_group_label": "Cohort 3", 
                "description": "Herceptin\u00ae (maintenance dose per the manufacturer's directions) followed by a subcutaneous injection of CpG 7909.", 
                "intervention_name": "Herceptin\u00ae", 
                "intervention_type": "Drug", 
                "other_name": "Trastuzumab"
            }, 
            {
                "arm_group_label": "Cohort 4", 
                "description": "0.16 mg/kg CpG 7909 by subcutaneous Injection once weekly until progression or 24 weeks", 
                "intervention_name": "0.16 mg/kg CpG 7909", 
                "intervention_type": "Drug", 
                "other_name": "PF-03512676, ProMune"
            }, 
            {
                "arm_group_label": "Cohort 4", 
                "description": "Herceptin\u00ae (maintenance dose per the manufacturer's directions) followed by a subcutaneous injection of CpG 7909.", 
                "intervention_name": "Herceptin\u00ae", 
                "intervention_type": "Drug", 
                "other_name": "Trastuzumab"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Trastuzumab"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": "CpG 7909 subcutaneous injection  combination with Herceptin\u00ae metastatic breast cancer.", 
        "lastchanged_date": "March 11, 2009", 
        "link": {
            "description": "To obtain contact information for a study center near you, click here.", 
            "url": "https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=C015&StudyName=CPG%207909%20Plus%20Herceptin%AE%20In%20Patients%20With%20Metastatic%20Breast%20Cancer"
        }, 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Berkely", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "94704"
                    }, 
                    "name": "Pfizer Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Orange", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "92868"
                    }, 
                    "name": "Pfizer Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Palm Springs", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "92262"
                    }, 
                    "name": "Pfizer Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "New Haven", 
                        "country": "United States", 
                        "state": "Connecticut", 
                        "zip": "06510"
                    }, 
                    "name": "Pfizer Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Washington", 
                        "country": "United States", 
                        "state": "District of Columbia", 
                        "zip": "20007-2197"
                    }, 
                    "name": "Pfizer Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Plantation", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "33324"
                    }, 
                    "name": "Pfizer Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Ann Arbor", 
                        "country": "United States", 
                        "state": "Michigan", 
                        "zip": "48109"
                    }, 
                    "name": "Pfizer Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Dearborn", 
                        "country": "United States", 
                        "state": "Michigan", 
                        "zip": "48126-2641"
                    }, 
                    "name": "Pfizer Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Detroit", 
                        "country": "United States", 
                        "state": "Michigan", 
                        "zip": "48202"
                    }, 
                    "name": "Pfizer Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "West Bloomfield", 
                        "country": "United States", 
                        "state": "Michigan", 
                        "zip": "48322-3013"
                    }, 
                    "name": "Pfizer Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Cleveland", 
                        "country": "United States", 
                        "state": "Ohio", 
                        "zip": "44195"
                    }, 
                    "name": "Pfizer Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Burlington", 
                        "country": "United States", 
                        "state": "Vermont", 
                        "zip": "05401-3456"
                    }, 
                    "name": "Pfizer Investigational Site"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "4", 
        "official_title": "A Phase I/II Open Label, Multi-Center, Dose-Escalation Study Of Subcutaneous CPG 7909 Plus Herceptin\u00ae In Patients With Metastatic Breast Cancer", 
        "overall_official": {
            "affiliation": "Pfizer", 
            "last_name": "Pfizer CT.gov Call Center", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "October 2003", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "measure": "Phase I: To evaluate the safety and tolerability of several dose levels of CPG 7909 (up to a maximum of 0.16 mg/kg) and to determine the maximum tolerated dose (MTD)* of CPG 7909 in combination with Herceptin\u00ae", 
                "safety_issue": "Yes", 
                "time_frame": "24 weeks"
            }, 
            {
                "measure": "Phase II: To evaluate tumor response and safety of CPG 7909 (at the MTD as determined in Phase I) in combination with Herceptin\u00ae in patients with metastatic breast cancer.", 
                "safety_issue": "Yes", 
                "time_frame": "24 weeks"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00043394"
        }, 
        "responsible_party": {
            "name_title": "Director, Clinical Trial Disclosure Group", 
            "organization": "Pfizer, Inc."
        }, 
        "secondary_outcome": [
            {
                "measure": "Phase I To evaluate tumor response, duration of response, time to disease progression, ECOG performance status, and survival time.", 
                "safety_issue": "No", 
                "time_frame": "24 weeks"
            }, 
            {
                "measure": "Phase II To evaluate duration of response, time to disease progression, ECOG performance status, and survival time.", 
                "safety_issue": "No", 
                "time_frame": "24 weeks"
            }
        ], 
        "source": "Pfizer", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Pfizer", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "September 2002", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2009"
    }, 
    "geocoordinates": {
        "Pfizer Investigational Site": "44.476 -73.212"
    }
}